Literature DB >> 17512020

Chlorpromazine exacerbates hepatic insulin sensitivity via attenuating insulin and leptin signaling pathway, while exercise partially reverses the adverse effects.

Sunmin Park1, Sang Mee Hong, Ji Eun Lee, So Ra Sung.   

Abstract

Investigated in this study are the effects and mechanisms of exercise and chlorpromazine (CPZ), a widely used conventional antipsychotic drug, on the hepatic insulin sensitivity of 90% pancreatectomized (Px) male Sprague-Dawley rats. The Px diabetic rats were provided with 0, 5, or 50 mg CPZ per kg of body weight (No-CPZ, LCPZ, or HCPZ) for 8 weeks, and half of each group had regular exercise. LCPZ did not exacerbate hepatic insulin sensitivity through insulin and leptin signaling in diabetic rats. However, HCPZ decreased whole-body glucose infusion rates in hyperinsulinemic clamped states, but not whole-body glucose uptake. This was due to the elevated hepatic glucose output in hyperinsulinemic states. The decreased hepatic insulin sensitivity was associated with insulin receptor substrate-2 (IRS2) protein levels in the liver. Decreased IRS2 levels attenuated hepatic insulin and leptin signaling pathways in hyperinsulinemic states, which elevated glucose production by inducing phosphoenolpyruvate carboxykinase expression. Long-term exercise recovered hepatic insulin sensitivity attenuated by HCPZ to reduce the hepatic glucose output in hyperinsulinemic clamped states. This recovery was related to enhanced insulin and leptin signaling via increased IRS2 gene and protein levels by activating the cAMP responding element-binding protein, but exercise improved only insulin signaling. In conclusion, HCPZ exacerbates hepatic insulin action by attenuating insulin and leptin signaling in type 2 diabetic rats, while regular exercise partially reverses the attenuation of hepatic insulin sensitivity by improving insulin signaling. Enhancement of insulin and leptin signaling through an induction of IRS2 may play an important role in improving hepatic glucose homeostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512020     DOI: 10.1016/j.lfs.2007.04.001

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.

Authors:  Heidi N Boyda; Ric M Procyshyn; Lurdes Tse; Erin Hawkes; Chen H Jin; Catherine C Y Pang; William G Honer; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2012-11       Impact factor: 6.186

Review 2.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

Review 3.  Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.

Authors:  Katrina Weston-Green; Xu-Feng Huang; Chao Deng
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

4.  A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease.

Authors:  James A Timmons; Andrew Anighoro; Robert J Brogan; Jack Stahl; Claes Wahlestedt; David Gordon Farquhar; Jake Taylor-King; Claude-Henry Volmar; William E Kraus; Stuart M Phillips
Journal:  Elife       Date:  2022-01-17       Impact factor: 8.713

5.  Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects.

Authors:  Kwang H Choi; Brandon W Higgs; Serge Weis; Jonathan Song; Ida C Llenos; Jeannette R Dulay; Robert H Yolken; Maree J Webster
Journal:  BMC Psychiatry       Date:  2009-09-16       Impact factor: 3.630

6.  Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways.

Authors:  V Mondelli; C Anacker; A C Vernon; A Cattaneo; S Natesan; M Modo; P Dazzan; S Kapur; C M Pariante
Journal:  Transl Psychiatry       Date:  2013-01-15       Impact factor: 6.222

Review 7.  Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain.

Authors:  Diana Grajales; Vitor Ferreira; Ángela M Valverde
Journal:  Cells       Date:  2019-10-29       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.